• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
              Advocacy & Research for Unlimited Lifespans


PAYWALL > Human geroprotector discovery by targeting the converging subnetworks of aging and age-related diseases

aging age-related diseases drug repurposing network pharmacology pharmacogenomics geroscience

  • Please log in to reply
No replies to this topic

#1 Engadin

  • Guest
  • 196 posts
  • 559
  • Location:Madrid
  • NO

Posted 05 November 2019 - 05:36 PM






B E H I N D   P A Y W A L L   S O U R C E :   GeroScience






A key goal of geroscience research is to identify effective interventions to extend human healthspan, the years of healthy life. Currently, majority of the geroprotectors are found by screening compounds in model organisms; whether they will be effective in humans is largely unknown. Here we present a new strategy called ANDRU (aging network based drug discovery) to help the discovery of human geroprotectors. It first identifies human aging subnetworks that putatively function at the interface between aging and age-related diseases; it then screens for pharmacological interventions that may “reverse” the age-associated transcriptional changes occurred in these subnetworks. We applied ANDRU to human adipose gene expression data from the Genotype Tissue Expression (GTEx) project. For the top 31 identified compounds, 19 of them showed at least some evidence supporting their function in improving metabolic traits or lifespan, which include type 2 diabetes drugs such as pioglitazone. As the query aging genes were refined to the ones with more intimate links to diseases, ANDRU identified more meaningful drug hits than the general approach without considering the underlying network structures. In summary, ANDRU represents a promising human data-driven strategy that may speed up the discovery of interventions to extend human healthspan.






Also tagged with one or more of these keywords: aging, age-related diseases, drug repurposing, network pharmacology, pharmacogenomics, geroscience

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users